Raymond James Financial
NMRA icon

Raymond James Financial’s Neumora Therapeutics NMRA Stock Holding History

Raymond James Financial’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-185
Closed -$136 – 6112
2025
Q2 		$136 Buy
+185
New +$140 ﹤0.01% 6815

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Raymond James Financial's NMRA Position: Q3 2025 in Review

Raymond James Financial sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 185 shares — an estimated $136 sold.

Raymond James Financial first reported a position in NMRA in Q2 2025 and held it in 1 quarter. The position peaked at $136 in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Raymond James Financial reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 185 Neumora Therapeutics shares in Q3 2025, an estimated $136.
  • Raymond James Financial first reported a position in Neumora Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Neumora Therapeutics position peaked at $136 in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.